Legend Biotech Corporation (NASDAQ:LEGN) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Will Genscript Cash Out of Legend Biotech in the Face of Fat Profit Temptation?
Is Legend Biotech Corporation (LEGN) a Good Growth Stock to Buy?
Genscript Biotech's US-Listed Unit Forecasts Up to $110 Million in January-June Loss
Sector Update: Health Care Stocks Higher Late Afternoon
Legend biotech (LEGN.US) is expected to have a net loss of up to 0.11 billion US dollars in the first half of the year after adjustment.
Legend biotech (LEGN.US) is expected to have a net loss of approximately $94.7 million to $0.1097 billion in the first half of 2024 after adjustments.
Genscript Bio: Legend Biotech expects a net loss of $75.4 million to $87.4 million in the first half of the year.
Genscript Bio (01548) announced that in the first half of 2024, Legend Biotech is expected to achieve a net loss after adjustment...
Express News | Legend Biotech Reports Preliminary Results; Expects Six-Month Adjusted Net Loss Of $(94.7)M - $(109.7)M
Legend Biotech | 6-K: Report of foreign private issuer (related to financial reporting)
Express News | Legend Biotech - for Six-Months Ended June 30, 2024, Expects to Record Adjusted Net Loss for Period of Approximately $94.7 Mln to $109.7 Mln
Express News | Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024
Express News | Legend Biotech Corporation H1 Net Income USD -75.4 Million
Warner Bros. Discovery & Coinbase Are Among 10 Large Cap Stocks That Shined Most Last Week (July 14-July 20): Are The Others In Your Portfolio?
Scotiabank Maintains Legend Biotech(LEGN.US) With Buy Rating, Raises Target Price to $70
Express News | Scotiabank Maintains Sector Outperform on Legend Biotech, Raises Price Target to $70
Cintas Posts Upbeat Earnings, Joins CommScope Holding, Virtu Financial And Other Big Stocks Moving Higher On Thursday
A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $70 to $94
Scotiabank Sticks to Their Buy Rating for Legend Biotech (LEGN)
Buy Rating on Legend Biotech: Strong Carvykti Sales and High Market Potential Signal Upside
Express News | Legend Biotech Corp : Scotiabank Raises Target Price to $70 From $65